A Post-Marketing Study of Pethidine in Indonesia: Safety Profile

Authors

  • Jarir At Thobari Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/RSUP Dr. Sardjito, Yogyakarta, Indonesia https://orcid.org/0000-0002-7035-4846
  • Jonathan Haposan Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/RSUP Dr. Sardjito, Yogyakarta, Indonesia; Pharmacy Installation, Dr. Sardjito General Hospital, Yogyakarta, Indonesia https://orcid.org/0000-0002-3455-6379
  • Muhammad Nurwahidin Pharmacy Installation, Dr. Sardjito General Hospital, Yogyakarta, Indonesia
  • Lukman Ade Chandra Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/RSUP Dr. Sardjito, Yogyakarta, Indonesia
  • Asri Riswiyanti Pharmacy Installation, Dr. Sardjito General Hospital, Yogyakarta, Indonesia
  • Djayanti Sari Department of Anaesthiology, Dr. Sardjito General Hospital, Yogyakarta, Indonesia https://orcid.org/0000-0002-4403-3539
  • Yunita Widyastuti Department of Anaesthiology, Dr. Sardjito General Hospital, Yogyakarta, Indonesia https://orcid.org/0000-0002-9717-2030
  • Sudarwanti Sudarwanti PT Kimia Farma Tbk, Jakarta, Indonesia
  • Nastia Hidayati PT Kimia Farma Tbk, Jakarta, Indonesia
  • Rianiasa Karunia Dewi PT Kimia Farma Tbk, Jakarta, Indonesia
  • Rita Purnamasari PT Kimia Farma Tbk, Jakarta, Indonesia
  • Dyah Juliana Pudjiati PT Kimia Farma Tbk, Jakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.8526

Keywords:

Pethidine, Meperidine, Post-marketing, Pharmacovigilance

Abstract

Introduction

Pethidine along with morphine and tramadol, is one of the frequently used drugs for postoperative pain management. It is important to ensure the safety of the product and ultimately the safety of the patients as users of the pethidine.

Methods

A post marketing surveillance study was conducted with a retrospective cross-sectional design using medical records and hospital pharmacy’s data in patients who were admitted to inpatient or emergency department of Dr. Sardjito General Hospital Yogyakarta between January and December 2016. The data was analyzed descriptively to estimate the proportion of adverse events (AEs) including serious adverse events (SAE).

Results

Of the 576 patients hospitalized at the at the Dr. Sardjito General Hospital, 200 medical records were selected using consecutive sampling method. A total of 120 of the 200 subjects were found to have 245 any Adverse Events (AE) including Serious Adverse Events (SAE) following the administration of pethidine. There were 23 classifications of expected AE and 148 classifications of unexpected AE following the administration of pethidine. The duration of AE/SAE found ranged from 0 to 11 days. A total of 101 (50.5%) and 85 (42.5%) subjects experienced AE/SAE with duration <24 hours and between 1 to 2 days, respectively. The longest duration of event was pain with duration of 11 days. There were 23 types of expected AE/SAE from pethidine found in subjects, with the highest number of expected AE/SAE were weakness, vomiting, and dizziness of 24 (25%), 16 (16.8%), and 10 (10.5%), respectively. The expert panel team concluded five types of unexpected SAEs which are possible to pethidine, including respiratory acidosis, urinary tract infections, acute kidney injury, icteric, and electrolyte imbalance.

Conclusion

A post-marketing surveillance study provides safety profile of 50 mg / ml pethidine in Indonesia. A total of 120 of the 200 subjects who received pethidine experienced 245 Adverse Events (AEs) or Serious Adverse Events (SAEs). AEs/SAEs were divided into 23 types of expected events and 148 types of unexpected events. Few numbers of SAEs were considered possible related to the pethidine according to expert panel review.

 

Keywords: pethidine, meperidine, post-marketing, pharmacovigilance

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Lee MC, Abrahams M. Pain and analgesics. In: Clinical Pharmacology. 11th ed., Vol. 14. Churchill Livingstone, London Elsevier Ltd.; 2012. p. 278-94. Available from: https://doi.org/10.1016/B978-0-7020-4084-9.00057-4 [Last accessed on 2021 Nov 01].

O’Connor A, Schug SA, Cardwell H. A comparison of the efficacy and safety of Morphine and Pethidine as analgesia for suspected renal colic in the emergency setting. J Accid Emerg Med. 2000;17(4):261-4. https://doi.org/10.1136/emj.17.4.261 PMid:10921813

Fisher J, Ganellin CR. Analogue-Based Drug Discovery. Research Triangle Park: Chemistry International - Newsmagazine for IUPAC: 2010. p. 12-5.

Ngan Kee WD. Intrathecal pethidine: Pharmacology and clinical applications. Anaesth Intensive Care. 1998;26(2):137-46. https://doi.org/10.1177/0310057X9802600202 PMid:9564390

Garimella V, Cellini C. Postoperative pain control. Clin Colon Rectal Surg. 2013;26(93):191-6. https://doi.org/10.1055/s-0033-1351138 PMid:24436674

Macintyre P, Bochner F, Wiltshire S, Molloy A. Does Pethidine still have a place in therapy? Aust Prescr. 2002;25:79-80.

Latta KS, Ginsberg B, Barkin RL. Meperidine: A critical review. Am J Ther. 2002;9(1):53-68. https://doi.org/10.1097/00045391-200201000-00010 PMid:11782820

Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: Evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy. 2004;24(6):776-83. https://doi.org/10.1592/phco.24.8.776.36066 PMid:15222668

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. https://doi.org/10.1038/clpt.1981.154 PMid:7249508

Golembiewski J. Safety concerns with meperidine. J Perianesthesia Nurs. 2002;17(2):123-5. https://doi.org/10.1053/jpan.2002.31661 Mid:11925585

Food and Drug Administration (FDA). Demerol Injection Prescribing Information; 2007. p. 37620. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021171s024s025lbl.pdf. [Last accessed on 2021 Nov 01].

Friesen KJ, Falk J, Bugden S. The safety of meperidine prescribing in older adults: A longitudinal population-based study. BMC Geriatr. 2016;16(1):1-7. Available from: https://doi.org/10.1186/s12877-016-0275-5 [Last accessed on 2021 Nov 01].

Radnay P, Boradman E, Mankikar D, Duncalf D. The effects of equi-analgesic doses of fentanyl, morphine and pentazocine on common bile duct pressure. Anesthetist. 1980;29(1):26-9. PMid:6104938

Mildh LH, Leino KA, Kirvelä OA. Effects of tramadol and meperidine on respiration, plasma catecholamine concentrations, and hemodynamics. J Clin Anesth. 1999;11(4):310-6. https://doi.org/10.1016/s0952-8180(99)00047-1 PMid:10470633

Hoseinkhan Z, Behzadi M. Morphine, pethidine and fentanyl in post-operative shivering control: A randomized clinical trial. Tehran Univ Med J TUMS Publ. 2006;64(12):57-63.

Dabir S, Jahandideh M, Abbasinazari M, Kouzekanani H, Parsa T, Radpay B. The efficacy of a single dose of pethidine, fentanyl, and morphine in treating postanesthesia shivering. Pak J Pharm Sci. 2011;24(4):513-7. PMid:21959813

Alfonsi P, Hongnat JM, Lebrault C, Chauvin M. The effects of pethidine, fentanyl and lignocaine on postanaesthetic shivering. Anaesthesia. 1995;50(3):214-7. https://doi.org/10.1111/j.1365-2044.1995.tb04559.x PMid:7717486

Meperidine Interaction. Available from: https://www.drugs.com/drug-interactions/meperidine.html. [Last accessed on 2021 Nov 01].

Downloads

Published

2022-03-19

How to Cite

1.
Thobari JA, Haposan J, Nurwahidin M, Chandra LA, Riswiyanti A, Sari D, Widyastuti Y, Sudarwanti S, Hidayati N, Dewi RK, Purnamasari R, Pudjiati DJ. A Post-Marketing Study of Pethidine in Indonesia: Safety Profile. Open Access Maced J Med Sci [Internet]. 2022 Mar. 19 [cited 2022 Jul. 1];10(A):519-24. Available from: https://oamjms.eu/index.php/mjms/article/view/8526